|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/22 BioRestorative Therapies, Inc. 10-K 12/31/21 92:16M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.82M
2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 44K
3: EX-10.15 Material Contract HTML 25K
4: EX-10.16 Material Contract HTML 25K
5: EX-10.17 Material Contract HTML 25K
6: EX-10.18 Material Contract HTML 30K
7: EX-10.19 Material Contract HTML 30K
8: EX-10.20 Material Contract HTML 107K
9: EX-10.21 Material Contract HTML 97K
10: EX-10.22 Material Contract HTML 31K
11: EX-10.23 Material Contract HTML 31K
12: EX-10.24 Material Contract HTML 30K
13: EX-10.25 Material Contract HTML 30K
14: EX-10.26 Material Contract HTML 30K
15: EX-23 Consent of Expert or Counsel HTML 23K
16: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
17: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
18: EX-32 Certification -- §906 - SOA'02 HTML 26K
24: R1 Cover HTML 96K
25: R2 Consolidated Balance Sheets HTML 117K
26: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K
27: R4 Consolidated Statements of Operations HTML 74K
28: R5 Consolidated Statements of Stockholders' Equity HTML 90K
(Deficit)
29: R6 Consolidated Statements of Cash Flows HTML 129K
30: R7 Organization and Business Operations HTML 40K
31: R8 Liquidity HTML 30K
32: R9 Summary of Significant Accounting Policies HTML 116K
33: R10 Property and Equipment HTML 52K
34: R11 Intangible Assets HTML 77K
35: R12 Accrued Expenses and Other Current Liabilities HTML 42K
36: R13 Notes Payable & Chapter 11 Reorganization HTML 222K
37: R14 Stockholders? Equity (Deficit) HTML 327K
38: R15 Derivative Liabilities HTML 51K
39: R16 Commitments and Contingencies HTML 66K
40: R17 Income Taxes HTML 100K
41: R18 Leases HTML 58K
42: R19 Subsequent Events HTML 31K
43: R20 Summary of Significant Accounting Policies HTML 169K
(Policies)
44: R21 Summary of Significant Accounting Policies HTML 56K
(Tables)
45: R22 Property and Equipment (Tables) HTML 49K
46: R23 Intangible Assets (Tables) HTML 77K
47: R24 Accrued Expenses and Other Current Liabilities HTML 40K
(Tables)
48: R25 Notes Payable & Chapter 11 Reorganization (Tables) HTML 93K
49: R26 Stockholders? Equity (Deficit) (Tables) HTML 282K
50: R27 Derivative Liabilities (Tables) HTML 47K
51: R28 Income Taxes (Tables) HTML 96K
52: R29 Leases (Tables) HTML 55K
53: R30 Organization and Business Operations (Details HTML 66K
Narrative)
54: R31 Liquidity (Details Narrative) HTML 40K
55: R32 Schedule of Reorganization Items, Net (Details) HTML 38K
56: R33 Schedule of Weighted Average Dilutive Common HTML 38K
Shares (Details)
57: R34 Schedule of Weighted Average Dilutive Common HTML 26K
Shares (Details) (Parenthetical)
58: R35 Summary of Significant Accounting Policies HTML 65K
(Details Narrative)
59: R36 Schedule of Property Plant and Equipment (Details) HTML 46K
60: R37 Property and Equipment (Details Narrative) HTML 26K
61: R38 Schedule of Intangible Assets by Major Class HTML 47K
(Details)
62: R39 Schedule of Finite Lived Intangible Assets HTML 38K
Amortization Expenses (Details)
63: R40 Schedule of Accrued Expenses and Other Current HTML 35K
Liabilities (Details)
64: R41 Schedule of Notes Payable Activity (Details) HTML 61K
65: R42 Schedule of Future Minimum Payments of Notes HTML 48K
Payable (Details)
66: R43 Notes Payable & Chapter 11 Reorganization (Details HTML 397K
Narrative)
67: R44 Schedule of Warrants Granted Assumptions (Details) HTML 41K
68: R45 Schedule of Warrant Activity (Details) HTML 61K
69: R46 Schedule of Stock Warrants (Details) HTML 76K
70: R47 Schedule of Stock Option Granted Assumptions HTML 39K
(Details)
71: R48 Schedule of Stock Option Activity (Details) HTML 53K
72: R49 Schedule of Stock Option by Exercise Price HTML 62K
(Details)
73: R50 Schedule of Unvested Restricted Stock Units HTML 35K
(Details)
74: R51 Schedule of Stock Option Expense (Details) HTML 37K
75: R52 Stockholders? Equity (Deficit) (Details Narrative) HTML 217K
76: R53 Summary of Changes in Fair Value of Level 3 HTML 35K
Derivative Liabilities (Details)
77: R54 Summary of Derivative Liabilities Fair Value HTML 39K
Assumption (Details)
78: R55 Derivative Liabilities (Details Narrative) HTML 39K
79: R56 Commitments and Contingencies (Details Narrative) HTML 163K
80: R57 Schedule of Net Deferred Tax Assets and HTML 47K
Liabilities (Details)
81: R58 Schedule of Income Tax Provision (Benefit) HTML 39K
(Details)
82: R59 Schedule of Statutory Federal Income Tax Rate HTML 37K
(Details)
83: R60 Income Taxes (Details Narrative) HTML 37K
84: R61 Schedule of Net Lease Cost and Other Supplemental HTML 39K
Lease Information (Details)
85: R62 Schedule of Future Minimum Payments Under HTML 37K
Non-Cancelable Leases for Operating Leases
(Details)
86: R63 Leases (Details Narrative) HTML 35K
87: R64 Subsequent Events (Details Narrative) HTML 42K
90: XML IDEA XML File -- Filing Summary XML 147K
88: XML XBRL Instance -- form10k_htm XML 2.48M
89: EXCEL IDEA Workbook of Financial Reports XLSX 117K
20: EX-101.CAL XBRL Calculations -- brtx-20211231_cal XML 178K
21: EX-101.DEF XBRL Definitions -- brtx-20211231_def XML 813K
22: EX-101.LAB XBRL Labels -- brtx-20211231_lab XML 1.36M
23: EX-101.PRE XBRL Presentations -- brtx-20211231_pre XML 1.06M
19: EX-101.SCH XBRL Schema -- brtx-20211231 XSD 200K
91: JSON XBRL Instance as JSON Data -- MetaLinks 413± 579K
92: ZIP XBRL Zipped Folder -- 0001493152-22-008184-xbrl Zip 514K
Exhibit 10.22
AMENDMENT NO. 2 TO
NON-QUALIFIED STOCK OPTION AWARD AGREEMENT
UNDER THE
BIORESTORATIVE THERAPIES, INC.
2021 STOCK INCENTIVE PLAN
This Amendment No. 2 to Non-Qualified Stock Option Award Agreement (this “Amendment”) is made and entered into as of December 10, 2021 (the “Effective Date”) by and between BioRestorative Therapies, Inc., a Delaware corporation (the “Company”), and Lance Alstodt (the “Participant”).
RECITALS
| A. | The Company granted to the Participant an option to purchase 1,173,917,974 shares of the Common Stock of the Company pursuant to the terms of a Non-Qualified Stock Option Award Agreement (the “Option”) under the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “Plan”) on March 18, 2021 (the “Grant Date”). |
| B. | The Company effected a 1-for-4,000 reverse split of its Common Stock on October 27, 2021 (the “Reverse Split”). |
| C. | On November 4, 2021, the Company and the Participant entered into Amendment No. 1 to Non-Qualified Stock Option Award Agreement to amend the Exercise Price per Share in the Option to reflect the then current Fair Market Value, to indicate that the number of Option Shares (after giving effect to the Reverse Split) is 293,479 and to amend the vesting schedule. |
| D. | The Company wishes to amend the Exercise Price per Share in the Option to reflect the current Fair Market Value. |
| E. | The Company and the Participant wish to enter into this Amendment, pursuant to Section 18 of the Option, to amend and modify the Option by the terms of this Amendment and preserve the remaining terms of the Option without modification or amendment. |
| F. | This Amendment is subject to stockholder approval of an amendment to the Plan which grants authority to the Board of Directors of the Company or a committee thereof to reduce the Exercise Price per Share in the Option (“Stockholder Approval”). |
AMENDMENT
In consideration of the above recitals, which are incorporated herein by reference, and the promises set forth in this Amendment and the Option, and for other good and valuable consideration, the nature and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:
| 1. | The Exercise Price per Share is hereby deleted and replaced with the following: |
Exercise Price per Share: $5.08
| 2. | The foregoing change to the Option is subject to Stockholder Approval. |
| 3. | Except as otherwise amended by this Amendment, all other provisions of the Option will remain unchanged and in full force and effect. |
***Signature Page to Follow***
C:
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
| BIORESTORATIVE THERAPIES, INC. | ||
| By: | ||
| Francisco Silva | ||
| VP of Research and Development | ||
| PARTICIPANT | ||
| Lance Alstodt | ||
***Signature Page to Amendment No. 2 to Non-Qualified Stock Option Award Agreement***
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/30/22 | |||
| For Period end: | 12/31/21 | |||
| 12/10/21 | ||||
| 11/4/21 | 3, 4, 8-A12B, 8-K, CERT, CORRESP, EFFECT, S-1/A, S-1MEF | |||
| 10/27/21 | ||||
| 3/18/21 | 10-K, 3, 4, 8-K, 8-K/A | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/12/24 BioRestorative Therapies, Inc. S-1/A 1:86K Certilman Balin … LLP/FA 4/01/24 BioRestorative Therapies, Inc. 10-K 12/31/23 80:9M M2 Compliance LLC/FA 3/27/23 BioRestorative Therapies, Inc. 10-K 12/31/22 79:7.4M M2 Compliance LLC/FA 2/07/23 BioRestorative Therapies, Inc. S-3 4:283K Certilman Balin … LLP/FA 11/14/22 BioRestorative Therapies, Inc. 10-Q 9/30/22 54:4M M2 Compliance LLC/FA 9/30/22 BioRestorative Therapies, Inc. POS AM 2:759K Certilman Balin … LLP/FA 8/16/22 BioRestorative Therapies, Inc. POS AM 2:764K Certilman Balin … LLP/FA 8/15/22 BioRestorative Therapies, Inc. 10-Q 6/30/22 59:4.5M M2 Compliance LLC/FA 5/16/22 BioRestorative Therapies, Inc. 10-Q 3/31/22 56:4.2M M2 Compliance LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/08/21 BioRestorative Therapies, Inc. 8-K:1,5,7,911/04/21 14:14M Certilman Balin … LLP/FA 3/19/21 BioRestorative Therapies, Inc. 8-K:5,9 3/18/21 8:492K Certilman Balin … LLP/FA 3/18/21 BioRestorative Therapies, Inc. 10-K 12/31/19 81:8.9M M2 Compliance LLC/FA 11/05/20 BioRestorative Therapies, Inc. 8-K:1,9 10/30/20 5:26M Certilman Balin … LLP/FA 3/29/19 BioRestorative Therapies, Inc. 10-K 12/31/18 94:8.6M M2 Compliance LLC/FA 3/30/16 BioRestorative Therapies, Inc. 10-K 12/31/15 73:9.3M Toppan Merrill/FA 12/23/14 BioRestorative Therapies, Inc. 8-K:3,5,9 12/19/14 6:329K Certilman Balin … LLP/FA 8/29/14 BioRestorative Therapies, Inc. 8-K:1,2,3,9 8/26/14 2:318K Certilman Balin … LLP/FA 4/16/12 BioRestorative Therapies, Inc. 10-K 12/31/11 46:4.4M Toppan Merrill/FA |